Get the Stockscreener App
0.9302
4.10%
-0.0398
After Hours:
.93
-0.0002
-0.02%
Renovorx Inc stock is traded at $0.9302, with a volume of 146.14K.
It is down -4.10% in the last 24 hours and down -11.41% over the past month.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
See More
Previous Close:
$0.97
Open:
$0.9601
24h Volume:
146.14K
Relative Volume:
0.52
Market Cap:
$34.09M
Revenue:
-
Net Income/Loss:
$-9.16M
P/E Ratio:
-1.6319
EPS:
-0.57
Net Cash Flow:
$-8.75M
1W Performance:
-2.18%
1M Performance:
-11.41%
6M Performance:
-15.44%
1Y Performance:
-19.81%
1-Day Range:
$0.93
$0.99
1-Week Range:
$0.93
$1.02
52-Week Range:
$0.7006
$1.45
Renovorx Inc Stock (RNXT) Company Profile
Name
Renovorx Inc
Sector
Industry
Phone
408-800-2649
Address
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
0.9302 | 35.55M | 0 | -9.16M | -8.75M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Renovorx Inc Stock (RNXT) Latest News
Aug Catalysts: What drives XYZGs stock price2025 EndofYear Setup & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
What’s the beta of RenovoRx Inc. stockJuly 2025 Snapshot & Accurate Buy Signal Notifications - mfd.ru
RenovoRx formation of RenovoCath Medical Advisory Board to support clinical and strategic initiatives - marketscreener.com
RenovoRx Establishes RenovoCath® Medical Advisory Board - Investing News Network
Renovorx Formation Of Renovocath Medical Advisory Board To Support Clinical And Strategic Initiatives - TradingView
RenovoRx, Inc. Establishes Medical Advisory Board to Advance RenovoCath Clinical Initiatives and Targeted Oncology Therapies - Quiver Quantitative
RenovoRx, Inc. Establishes RenovoCath Medical Advisory Board - marketscreener.com
Aug Ideas: Is RenovoRx Inc stock overvalued or fairly pricedWeekly Investment Recap & Safe Swing Trade Setup Alerts - baoquankhu1.vn
RenovoRx, Inc. Announces Change of Principal Accounting Officer - marketscreener.com
RenovoRx Appoints Veteran Executive Mark Voll as CFO - TipRanks
RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer - Investing News Network
30-year finance veteran joins RenovoRx to back cancer-device rollout - stocktitan.net
RenovoRx announces new clinical data on TAMP therapy platform - TipRanks
RenovoRx to Present New Clinical Data on Optimizing Drug Delivery in Solid Tumors at 2026 Society of Interventional Oncology Annual Meeting - Quiver Quantitative
How real-time pressure readings could sharpen chemo targeting - Stock Titan
Exit Recap: Is SunCar Technology Group Inc Equity Warrant forming a breakout patternJuly 2025 Market Mood & Community Trade Idea Sharing Platform - baoquankhu1.vn
RenovoRx (NASDAQ:RNXT) Upgraded at Jones Trading - Defense World
Pharma News: How does RenovoRx Inc perform in inflationary periods2025 Volume Leaders & Weekly Momentum Stock Picks - baoquankhu1.vn
Jones Trading initiates coverage on RenovoRx stock with Buy rating By Investing.com - Investing.com South Africa
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors - The Globe and Mail
Jones Trading initiates coverage on RenovoRx stock with Buy rating - Investing.com
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting - BioSpace
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 S - The National Law Review
RenovoRx, Inc. (NASDAQ:RNXT) Is Expected To Breakeven In The Near Future - simplywall.st
Agah Ramtin, chief medical officer at RenovoRx, buys $9975 in shares By Investing.com - Investing.com Nigeria
Agah Ramtin, chief medical officer at RenovoRx, buys $9975 in shares - Investing.com India
RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center - Investing News Network
RenovoRx Reports Growing Adoption of RenovoCath Device by U.S. Cancer Centers, Enhancing Targeted Oncology Treatment - Quiver Quantitative
RenovoRx, Inc. Expands RenovoCath®? Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center - marketscreener.com
Chemo-delivery device now used at nine U.S. cancer centers - Stock Titan
Loss-Making RenovoRx, Inc. (NASDAQ:RNXT) Expected To Breakeven In The Medium-Term - Yahoo Finance
Dividend Watch: Will RenovoRx Inc outperform tech stocks2025 Major Catalysts & High Accuracy Investment Signals - baoquankhu1.vn
Jobs Data: Is RenovoRx Inc stock a value trapTrade Volume Summary & Real-Time Volume Triggers - baoquankhu1.vn
Gap Down: Will RenovoRx Inc benefit from rate cuts2025 Key Lessons & Intraday High Probability Alerts - baoquankhu1.vn
Bear Alert: What is RenovoRx Incs book value per share2025 Fundamental Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Pullback Watch: Will RenovoRx Inc outperform its industry peersJuly 2025 Macro Moves & Precise Swing Trade Alerts - baoquankhu1.vn
RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026 - Investing News Network
RenovoRx CEO to Provide Update on Targeted Oncology Therapies at AlphaNorth Capital Event - Quiver Quantitative
Market Fear: Can RenovoRx Inc expand its profit marginsWeekly Market Outlook & Weekly Setup with ROI Potential - baoquankhu1.vn
Aug Setups: Should value investors consider RenovoRx IncJuly 2025 Update & Safe Capital Growth Stock Tips - baoquankhu1.vn
RenovoRx, Inc. (RNXT) Reports Q3 Loss, Lags Revenue Estimates - MSN
How RenovoRx Inc. stock reacts to inflationary pressuresEarnings Miss & Reliable Intraday Trade Plans - ulpravda.ru
Will RenovoRx Inc. stock deliver better than expected guidanceJuly 2025 Setups & Long-Term Capital Growth Strategies - ulpravda.ru
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech - The Manila Times
RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026 - Sahm
Will RenovoRx Inc. stock reach all time highs in 20252025 Market Outlook & Low Risk High Win Rate Picks - Улправда
Is RenovoRx Inc. stock resilient to inflationJuly 2025 Momentum & Capital Protection Trade Alerts - ulpravda.ru
How sustainable is RenovoRx Inc. stock dividend payout2025 Risk Factors & Weekly High Potential Stock Alerts - Улправда
Investor Mood: Will RenovoRx Inc stock see PE expansionMarket Sentiment Report & Real-Time Buy Zone Alerts - moha.gov.vn
Can RenovoRx Inc. stock continue upward trendTrade Risk Assessment & Growth Focused Stock Pick Reports - ulpravda.ru
Renovorx Inc Stock (RNXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):